Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “(2 g ERT + 2 g ZID) 4 g intravenously (IV) once daily (q24h) for 7 to 10 days”In the company’s words, NCT07840105 on ClinicalTrials.gov
- Tested for
- Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis
- Main trialPhase 2
- “This is a Phase 2 randomized open label multicentre three arm comparative study evaluating the efficacy safety tolerability and pharmacokinetics of intravenous ertapenem zidebactam ERT ZID compared with ceftazidime avibactam CAZ AVI in adults with complicated urinary tract infection cUTI or acute pyelonephritis AP. Approximately 279 hospitalized participants aged 18 years and above will be enrolled from approximately 30 study sites in India and Europe and randomized in a 1 to 1 to 1 ratio to receive ERT ZID for 5 to 7 days ERT ZID for 7 to 10 days or CAZ AVI for 7 to 10 days. The primary…”In the company’s words, NCT07840105 on ClinicalTrials.gov
- Other names
- Ertapenem-zidebactam
Other drugs for Acute Pyelonephritis
- U101TCM Biotech International Corp. · Phase 3
- Candidate UTI vaccineGSK · Phase 1/2
- LBP-EC01Locus Biosciences · Phase 2
- GepotidacinGSK · Phase 1
- JKN2501Joincare Pharmaceutical Group Industry Co., Ltd · Phase 1
Coming up1
- 1 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Sep 2027 | This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026